Yijun Jia, Tao Jiang, Xuefei Li, Chao Zhao, Limin Zhang, Sha Zhao, Xiaozhen Liu, Meng Qiao, Jiawei Luo, Jinpeng Shi, Hui Yang, Yan Wang, Lei Xi, Shijia Zhang, Guanghui Gao, Chunxia Su, Shengxiang Ren, Caicun Zhou. Oncol Lett 2017
Times Cited: 22
Times Cited: 22
Times Cited
Times Co-cited
Similarity
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou,[...]. Clin Cancer Res 2017
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou,[...]. Clin Cancer Res 2017
54
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
45
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Ferdinandos Skoulidis, Lauren A Byers, Lixia Diao, Vassiliki A Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R Parra, Jaime Rodriguez Canales,[...]. Cancer Discov 2015
Ferdinandos Skoulidis, Lauren A Byers, Lixia Diao, Vassiliki A Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R Parra, Jaime Rodriguez Canales,[...]. Cancer Discov 2015
40
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Nathan T Ihle, Lauren A Byers, Edward S Kim, Pierre Saintigny, J Jack Lee, George R Blumenschein, Anne Tsao, Suyu Liu, Jill E Larsen, Jing Wang,[...]. J Natl Cancer Inst 2012
Nathan T Ihle, Lauren A Byers, Edward S Kim, Pierre Saintigny, J Jack Lee, George R Blumenschein, Anne Tsao, Suyu Liu, Jill E Larsen, Jing Wang,[...]. J Natl Cancer Inst 2012
36
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Nan Chen, Wenfeng Fang, Zhong Lin, Peijian Peng, Juan Wang, Jianhua Zhan, Shaodong Hong, Jiaxing Huang, Lin Liu, Jin Sheng,[...]. Cancer Immunol Immunother 2017
Nan Chen, Wenfeng Fang, Zhong Lin, Peijian Peng, Juan Wang, Jianhua Zhan, Shaodong Hong, Jiaxing Huang, Lin Liu, Jin Sheng,[...]. Cancer Immunol Immunother 2017
36
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B Solit, Matthew Hellmann,[...]. Clin Cancer Res 2018
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B Solit, Matthew Hellmann,[...]. Clin Cancer Res 2018
36
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Snjezana Dogan, Ronglai Shen, Daphne C Ang, Melissa L Johnson, Sandra P D'Angelo, Paul K Paik, Edyta B Brzostowski, Gregory J Riely, Mark G Kris, Maureen F Zakowski,[...]. Clin Cancer Res 2012
Snjezana Dogan, Ronglai Shen, Daphne C Ang, Melissa L Johnson, Sandra P D'Angelo, Paul K Paik, Edyta B Brzostowski, Gregory J Riely, Mark G Kris, Maureen F Zakowski,[...]. Clin Cancer Res 2012
36
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
36
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
Frances A Shepherd, Caroline Domerg, Pierre Hainaut, Pasi A Jänne, Jean-Pierre Pignon, Stephen Graziano, Jean-Yves Douillard, Elizabeth Brambilla, Thierry Le Chevalier, Lesley Seymour,[...]. J Clin Oncol 2013
Frances A Shepherd, Caroline Domerg, Pierre Hainaut, Pasi A Jänne, Jean-Pierre Pignon, Stephen Graziano, Jean-Yves Douillard, Elizabeth Brambilla, Thierry Le Chevalier, Lesley Seymour,[...]. J Clin Oncol 2013
31
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Ernest Nadal, Guoan Chen, John R Prensner, Hiroe Shiratsuchi, Christine Sam, Lili Zhao, Gregory P Kalemkerian, Dean Brenner, Jules Lin, Rishindra M Reddy,[...]. J Thorac Oncol 2014
Ernest Nadal, Guoan Chen, John R Prensner, Hiroe Shiratsuchi, Christine Sam, Lili Zhao, Gregory P Kalemkerian, Dean Brenner, Jules Lin, Rishindra M Reddy,[...]. J Thorac Oncol 2014
31
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.
M C Garassino, M Marabese, P Rusconi, E Rulli, O Martelli, G Farina, A Scanni, M Broggini. Ann Oncol 2011
M C Garassino, M Marabese, P Rusconi, E Rulli, O Martelli, G Farina, A Scanni, M Broggini. Ann Oncol 2011
31
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
31
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R Janes, Jingchuan Zhang, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Xin Guo, Yuching Chen, Anjali Babbar, Sarah J Firdaus, Levan Darjania,[...]. Cell 2018
Matthew R Janes, Jingchuan Zhang, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Xin Guo, Yuching Chen, Anjali Babbar, Sarah J Firdaus, Levan Darjania,[...]. Cell 2018
31
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, Nicolas Brandone, Mohamed Boucekine, Mathieu Grangeon, Solène Chaleat, Natalyia Khobta, Julie Milia, Laurent Mhanna,[...]. J Thorac Oncol 2019
Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, Nicolas Brandone, Mohamed Boucekine, Mathieu Grangeon, Solène Chaleat, Natalyia Khobta, Julie Milia, Laurent Mhanna,[...]. J Thorac Oncol 2019
31
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Chengming Liu, Sufei Zheng, Runsen Jin, Xinfeng Wang, Feng Wang, Ruochuan Zang, Haiyan Xu, Zhiliang Lu, Jianbing Huang, Yuanyuan Lei,[...]. Cancer Lett 2020
Chengming Liu, Sufei Zheng, Runsen Jin, Xinfeng Wang, Feng Wang, Ruochuan Zang, Haiyan Xu, Zhiliang Lu, Jianbing Huang, Yuanyuan Lei,[...]. Cancer Lett 2020
31
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Pasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Juergen Wolf, Pilar Garrido,[...]. JAMA 2017
Pasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Juergen Wolf, Pilar Garrido,[...]. JAMA 2017
27
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
M B Schabath, E A Welsh, W J Fulp, L Chen, J K Teer, Z J Thompson, B E Engel, M Xie, A E Berglund, B C Creelan,[...]. Oncogene 2016
M B Schabath, E A Welsh, W J Fulp, L Chen, J K Teer, Z J Thompson, B E Engel, M Xie, A E Berglund, B C Creelan,[...]. Oncogene 2016
27
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Matthew P Patricelli, Matthew R Janes, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Linda V Kessler, Yuching Chen, Jeff M Kucharski, Jun Feng, Tess Ely,[...]. Cancer Discov 2016
Matthew P Patricelli, Matthew R Janes, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Linda V Kessler, Yuching Chen, Jeff M Kucharski, Jun Feng, Tess Ely,[...]. Cancer Discov 2016
27
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Alona Zer, Keyue Ding, Siow Ming Lee, Glenwood D Goss, Lesley Seymour, Peter M Ellis, Allan Hackshaw, Penelope A Bradbury, Lei Han, Christopher J O'Callaghan,[...]. J Thorac Oncol 2016
Alona Zer, Keyue Ding, Siow Ming Lee, Glenwood D Goss, Lesley Seymour, Peter M Ellis, Allan Hackshaw, Penelope A Bradbury, Lei Han, Christopher J O'Callaghan,[...]. J Thorac Oncol 2016
27
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Matthias Scheffler, Michaela A Ihle, Rebecca Hein, Sabine Merkelbach-Bruse, Andreas H Scheel, Janna Siemanowski, Johannes Brägelmann, Anna Kron, Nima Abedpour, Frank Ueckeroth,[...]. J Thorac Oncol 2019
Matthias Scheffler, Michaela A Ihle, Rebecca Hein, Sabine Merkelbach-Bruse, Andreas H Scheel, Janna Siemanowski, Johannes Brägelmann, Anna Kron, Nima Abedpour, Frank Ueckeroth,[...]. J Thorac Oncol 2019
27
Drugging the undruggable RAS: Mission possible?
Adrienne D Cox, Stephen W Fesik, Alec C Kimmelman, Ji Luo, Channing J Der. Nat Rev Drug Discov 2014
Adrienne D Cox, Stephen W Fesik, Alec C Kimmelman, Ji Luo, Channing J Der. Nat Rev Drug Discov 2014
27
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
27
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Rodrigo Romero, Volkan I Sayin, Shawn M Davidson, Matthew R Bauer, Simranjit X Singh, Sarah E LeBoeuf, Triantafyllia R Karakousi, Donald C Ellis, Arjun Bhutkar, Francisco J Sánchez-Rivera,[...]. Nat Med 2017
Rodrigo Romero, Volkan I Sayin, Shawn M Davidson, Matthew R Bauer, Simranjit X Singh, Sarah E LeBoeuf, Triantafyllia R Karakousi, Donald C Ellis, Arjun Bhutkar, Francisco J Sánchez-Rivera,[...]. Nat Med 2017
22
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Jonathan M Ostrem, Ulf Peters, Martin L Sos, James A Wells, Kevan M Shokat. Nature 2013
Jonathan M Ostrem, Ulf Peters, Martin L Sos, James A Wells, Kevan M Shokat. Nature 2013
22
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
P A Jänne, I Smith, G McWalter, H Mann, B Dougherty, J Walker, M C M Orr, D R Hodgson, A T Shaw, J R Pereira,[...]. Br J Cancer 2015
P A Jänne, I Smith, G McWalter, H Mann, B Dougherty, J Walker, M C M Orr, D R Hodgson, A T Shaw, J R Pereira,[...]. Br J Cancer 2015
22
A comprehensive survey of Ras mutations in cancer.
Ian A Prior, Paul D Lewis, Carla Mattos. Cancer Res 2012
Ian A Prior, Paul D Lewis, Carla Mattos. Cancer Res 2012
22
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.
Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent, Ignacio Gil-Bazo. Mol Cancer 2018
Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent, Ignacio Gil-Bazo. Mol Cancer 2018
22
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Ondrej Fiala, Milos Pesek, Jindrich Finek, Lucie Benesova, Barbora Belsanova, Marek Minarik. Cancer Genet 2013
Ondrej Fiala, Milos Pesek, Jindrich Finek, Lucie Benesova, Barbora Belsanova, Marek Minarik. Cancer Genet 2013
18
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Helena Linardou, Issa J Dahabreh, Dimitra Kanaloupiti, Fotios Siannis, Dimitrios Bafaloukos, Paris Kosmidis, Christos A Papadimitriou, Samuel Murray. Lancet Oncol 2008
Helena Linardou, Issa J Dahabreh, Dimitra Kanaloupiti, Fotios Siannis, Dimitrios Bafaloukos, Paris Kosmidis, Christos A Papadimitriou, Samuel Murray. Lancet Oncol 2008
18
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.
C Mascaux, N Iannino, B Martin, M Paesmans, T Berghmans, M Dusart, A Haller, P Lothaire, A-P Meert, S Noel,[...]. Br J Cancer 2005
C Mascaux, N Iannino, B Martin, M Paesmans, T Berghmans, M Dusart, A Haller, P Lothaire, A-P Meert, S Noel,[...]. Br J Cancer 2005
18
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
18
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.
Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um. J Pathol Transl Med 2016
Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um. J Pathol Transl Med 2016
18
KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.
Weimin Gao, Jide Jin, Jinling Yin, Stephanie Land, Autumn Gaither-Davis, Neil Christie, James D Luketich, Jill M Siegfried, Phouthone Keohavong. Mol Carcinog 2017
Weimin Gao, Jide Jin, Jinling Yin, Stephanie Land, Autumn Gaither-Davis, Neil Christie, James D Luketich, Jill M Siegfried, Phouthone Keohavong. Mol Carcinog 2017
23
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song,[...]. Nat Med 2008
Jeffrey A Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R Guimaraes, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A Perera, Youngchul Song,[...]. Nat Med 2008
18
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Shohei Koyama, Esra A Akbay, Yvonne Y Li, Amir R Aref, Ferdinandos Skoulidis, Grit S Herter-Sprie, Kevin A Buczkowski, Yan Liu, Mark M Awad, Warren L Denning,[...]. Cancer Res 2016
Shohei Koyama, Esra A Akbay, Yvonne Y Li, Amir R Aref, Ferdinandos Skoulidis, Grit S Herter-Sprie, Kevin A Buczkowski, Yan Liu, Mark M Awad, Warren L Denning,[...]. Cancer Res 2016
18
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).
S Dearden, J Stevens, Y-L Wu, D Blowers. Ann Oncol 2013
S Dearden, J Stevens, Y-L Wu, D Blowers. Ann Oncol 2013
18
RAS oncogenes: weaving a tumorigenic web.
Yuliya Pylayeva-Gupta, Elda Grabocka, Dafna Bar-Sagi. Nat Rev Cancer 2011
Yuliya Pylayeva-Gupta, Elda Grabocka, Dafna Bar-Sagi. Nat Rev Cancer 2011
18
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Gregory J Riely, Mark G Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A Chitale, Khedoudja Nafa, Elyn R Riedel, Meier Hsu, William Pao,[...]. Clin Cancer Res 2008
Gregory J Riely, Mark G Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A Chitale, Khedoudja Nafa, Elyn R Riedel, Meier Hsu, William Pao,[...]. Clin Cancer Res 2008
18
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Wouter W Mellema, Anne-Marie C Dingemans, Erik Thunnissen, Peter J F Snijders, Jules Derks, Daniëlle A M Heideman, Robertjan Van Suylen, Egbert F Smit. J Thorac Oncol 2013
Wouter W Mellema, Anne-Marie C Dingemans, Erik Thunnissen, Peter J F Snijders, Jules Derks, Daniëlle A M Heideman, Robertjan Van Suylen, Egbert F Smit. J Thorac Oncol 2013
18
Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
Kevin Wood, Thomas Hensing, Raeva Malik, Ravi Salgia. JAMA Oncol 2016
Kevin Wood, Thomas Hensing, Raeva Malik, Ravi Salgia. JAMA Oncol 2016
18
Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Bibhu Ranjan Das, Sangeet Bhaumik, Firoz Ahmad, Aziz Mandsaurwala, Heena Satam. Pathol Oncol Res 2015
Bibhu Ranjan Das, Sangeet Bhaumik, Firoz Ahmad, Aziz Mandsaurwala, Heena Satam. Pathol Oncol Res 2015
40
The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Benjamin Izar, Haiyu Zhou, Rebecca S Heist, Christopher G Azzoli, Alona Muzikansky, Emily E F Scribner, Lindsay A Bernardo, Dora Dias-Santagata, Anthony J Iafrate, Michael Lanuti. J Thorac Oncol 2014
Benjamin Izar, Haiyu Zhou, Rebecca S Heist, Christopher G Azzoli, Alona Muzikansky, Emily E F Scribner, Lindsay A Bernardo, Dora Dias-Santagata, Anthony J Iafrate, Michael Lanuti. J Thorac Oncol 2014
18
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Jacqueline V Aredo, Sukhmani K Padda, Christian A Kunder, Summer S Han, Joel W Neal, Joseph B Shrager, Heather A Wakelee. Lung Cancer 2019
Jacqueline V Aredo, Sukhmani K Padda, Christian A Kunder, Summer S Han, Joel W Neal, Joseph B Shrager, Heather A Wakelee. Lung Cancer 2019
18
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
Badi El Osta, Madhusmita Behera, Sungjin Kim, Lynne D Berry, Gabriel Sica, Rathi N Pillai, Taofeek K Owonikoko, Mark G Kris, Bruce E Johnson, David J Kwiatkowski,[...]. J Thorac Oncol 2019
Badi El Osta, Madhusmita Behera, Sungjin Kim, Lynne D Berry, Gabriel Sica, Rathi N Pillai, Taofeek K Owonikoko, Mark G Kris, Bruce E Johnson, David J Kwiatkowski,[...]. J Thorac Oncol 2019
18
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
Pascale Tomasini, Preet Walia, Catherine Labbe, Kevin Jao, Natasha B Leighl. Oncologist 2016
Pascale Tomasini, Preet Walia, Catherine Labbe, Kevin Jao, Natasha B Leighl. Oncologist 2016
18
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
S Li, L Li, Y Zhu, C Huang, Y Qin, H Liu, L Ren-Heidenreich, B Shi, H Ren, X Chu,[...]. Br J Cancer 2014
S Li, L Li, Y Zhu, C Huang, Y Qin, H Liu, L Ren-Heidenreich, B Shi, H Ren, X Chu,[...]. Br J Cancer 2014
13
The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Anna Biernacka, Peter D Tsongalis, Jason D Peterson, Francine B de Abreu, Candice C Black, Edward J Gutmann, Xiaoying Liu, Laura J Tafe, Christopher I Amos, Gregory J Tsongalis. Cancer Genet 2016
Anna Biernacka, Peter D Tsongalis, Jason D Peterson, Francine B de Abreu, Candice C Black, Edward J Gutmann, Xiaoying Liu, Laura J Tafe, Christopher I Amos, Gregory J Tsongalis. Cancer Genet 2016
13
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.
Anurag Singh, Patricia Greninger, Daniel Rhodes, Louise Koopman, Sheila Violette, Nabeel Bardeesy, Jeff Settleman. Cancer Cell 2009
Anurag Singh, Patricia Greninger, Daniel Rhodes, Louise Koopman, Sheila Violette, Nabeel Bardeesy, Jeff Settleman. Cancer Cell 2009
13
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
Martin Svaton, Ondrej Fiala, Milos Pesek, Zbynek Bortlicek, Marek Minarik, Lucie Benesova, Ondrej Topolcan. Anticancer Res 2016
Martin Svaton, Ondrej Fiala, Milos Pesek, Zbynek Bortlicek, Marek Minarik, Lucie Benesova, Ondrej Topolcan. Anticancer Res 2016
14
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.